Chief Scientific Officer · Immunologist

Alex Abel

CSO, LEAH Labs  ·  Cell Therapy & Immunology

Alex Abel is Chief Scientific Officer at LEAH Labs, a gene therapy company developing CAR-T cell therapies. His research background spans NK cell biology, immune cytoskeletal signaling, and cell-based immunotherapy. He has co-authored work on AI-driven CAR-T design validation, NK cell development and maturation, and mechanisms of innate immune cytotoxicity.

NK Cell Biology CAR-T Cell Therapy Innate Immunology Cell-Based Immunotherapy IQGAP1 Signaling
LEAH Labs → PubMed →
Publications

Selected works

"Validation and analysis of 12,000 AI-driven CAR-T designs in the Bits to Binders competition"
Kosonocky CW, Abel AM, Feller AL, Cifuentes Rieffer AE et al.  ·  bioRxiv · 2026
PMID 41867703
"MyD88 is an essential regulator of NK cell-mediated clearance of MCMV infection"
Dixon KJ, Siebert JR, Wang D, Abel AM et al.  ·  Molecular Immunology · 2021
PMID 34242922
"In Vivo Assessment of NK Cell-Mediated Cytotoxicity by Adoptively Transferred Splenocyte Rejection"
Schloemer NJ, Abel AM, Thakar MS, Malarkannan S  ·  Methods in Molecular Biology · 2020
PMID 31776923
"Natural Killer Cells: Development, Maturation, and Clinical Utilization"
Abel AM, Yang C, Thakar MS, Malarkannan S  ·  Frontiers in Immunology · 2018
PMID 30150991
"IQ Domain-Containing GTPase-Activating Protein 1 Regulates Cytoskeletal Reorganization and Facilitates NKG2D-Mediated Mechanosensing"
Abel AM, Tiwari AA, Gerbec ZJ, Siebert JR et al.  ·  Frontiers in Immunology · 2018
PMID 29892299
"IQGAP1: insights into the function of a molecular puppeteer"
Abel AM, Schuldt KM, Rajasekaran K, Hwang D et al.  ·  Molecular Immunology · 2015
PMID 25733387

View full publication list on PubMed →